Latest

19:29
[ CFMEE (09630.HK): Proposes to establish wholly owned subsidiary Jishiwei (Shanghai) Technology with RMB 100 million investment ] NewTimeSpace News: On 26 August 2026, CFMEE (09630.HK) published an overseas regulatory announcement that its board has approved the establishment of a wholly owned subsidiary, Jishiwei (Shanghai) Technology Co., Ltd. (provisional name), with an investment of RMB 100 million of own or self-raised funds and a 100% shareholding, to improve its semiconductor equipment business footprint and enhance service coverage of the Yangtze River Delta and the national market; the investment does not require shareholders' meeting approval and does not constitute a connected transaction or major asset restructuring.
Tag： CFMEE09630.HKexternal investment
19:22
[ CREALITY (03388.HK): Proposes to acquire land by public tender and invest in additive manufacturing headquarters ] NewTimeSpace News: On 26 August 2026, CREALITY (03388.HK) announced that the board has approved participation in a public tender for the acquisition of a land parcel in the South China Logistics Park, Longhua District, Shenzhen, to build its additive manufacturing business headquarters and innovation center, with a total investment expected not to exceed RMB 550 million (including the land premium); the Proposed Land Acquisition remains subject to the outcome of the public tender process and approvals of the relevant authorities, and is expected to constitute a discloseable transaction (highest applicable percentage ratio exceeding 5% but below 25%) if materialized.
Tag： CREALITY03388.HKacquisition
19:13
[ BOAN BIOTECH (06955.HK): IND application for BA2201 (TL1A/IL-23) accepted by CDE ] NewTimeSpace News: On 26 August 2026, BOAN BIOTECH (06955.HK) announced that the IND application for BA2201, a long-acting bispecific antibody targeting TL1A and IL-23 independently developed by the Company, has been accepted by the CDE for the treatment of IBD including Crohn's disease and ulcerative colitis, expected to become one of the first TL1A/IL-23 bispecific antibodies to enter clinical stage in China; preclinical data showed superior efficacy compared with TL1A or IL-23 monotherapy.
Tag： BOAN BIOTECH06955.HKClinical Trial
19:09
[ SIRNAOMICS-B (02257.HK): Deemed disposal of equity interest in subsidiary following RMB 30 million investment, repurchase right granted to investor ] NewTimeSpace News: On 26 August 2026, SIRNAOMICS-B (02257.HK) announced that an investor will inject RMB 30 million into subsidiary Damien Vaccine (Guangzhou) (based on a RMB 500 million pre-investment valuation), diluting the seller RNAimmune's stake from 100% to 94.34% and constituting a deemed disposal; a repurchase right was granted to the investor on the same day (triggered by, among others, failure to complete a qualified IPO by end-2032), with the redemption price equal to 100% of the investment amount plus simple interest at 8% per annum; both the deemed disposal and the granting of the repurchase right constitute discloseable transactions.
Tag： SIRNAOMICS-B02257.HKDisposal
19:06
[ CM BANK (03968.HK): Appoints Wang Xiaoqing as authorized representative and adjusts board committee membership ] NewTimeSpace News: On 26 August 2026, CM BANK (03968.HK) announced the appointment of Mr. Wang Xiaoqing, executive director and President, as the authorized representative under Rule 3.05 of the Listing Rules (term until the expiration of the 13th board session), together with his appointment as member of the Strategy and Sustainable Development Committee and the Nomination Committee; the membership of the Related Party Transaction Committee was also adjusted, with Mr. Huang Yushan appointed as chairman and Mr. Jiang Chaoyang as member.
Tag： CM BANK03968.HKBoard Change
19:02
[ MAN YUE TECH(00894.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at HKD 9.19 million, YoY increase of 108.6% ] NewTimeSpace News: August 26, 2026, MAN YUE TECH(00894.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at HKD 918.61 million, increased by 12.49% YoY.
Tag： MAN YUE TECH00894.HKprofit growth
19:02
[ NCI(01336.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 22.79 billion, YoY increase of 54.02% ] NewTimeSpace News: August 26, 2026, NCI(01336.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 81.55 billion, increased by 17.46% YoY.
Tag： NCI01336.HKprofit growth
19:02
[ UNI MEDICAL(02666.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 1.26 billion, YoY increase of 2.8% ] NewTimeSpace News: August 26, 2026, UNI MEDICAL(02666.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 7.1 billion, decreased by 6.33% YoY
Tag： UNI MEDICAL02666.HKprofit growth
19:01
[ RUIYUAN ICTECH (08249.HK): Zheng Chengjie resigns as joint company secretary, Zou Jing appointed as authorized representative ] NewTimeSpace News: On 26 August 2026, RUIYUAN ICTECH (08249.HK) announced the resignation of Mr. Zheng Chengjie as joint company secretary and authorized representative under Rule 5.24 of the GEM Listing Rules due to other work arrangements, remaining as the process agent under the Companies Ordinance; Ms. Zou Jing will serve as the sole company secretary and has been appointed as the authorized representative under the Listing Rules, with Mr. Zheng appointed as her alternate.
Tag： RUIYUAN ICTECH08249.HKresignation
18:59
[ JUFEEL (08611.HK): Results of rights issue on basis of one rights share for one share held, approximately 14.62% of rights shares allotted ] NewTimeSpace News: On 26 August 2026, JUFEEL (08611.HK) announced the results of the rights issue on the basis of one rights share for one share held at HKD 0.60 per share: valid acceptances covered 26,594,196 rights shares, and 49,420,000 unsubscribed shares were placed at HKD 0.60 per share to not fewer than six placees; the rights issue became unconditional on 19 August 2026 with net proceeds of approximately HKD 43.0 million, and trading of the rights shares is expected to commence on 28 August 2026.
Tag： JUFEEL08611.HKrights issue
18:52
[ HOPSON DEV HOLD (00754.HK): Appoints independent internal control consultant Deloitte, trading suspension continues ] NewTimeSpace News: On 26 August 2026, HOPSON DEV HOLD (00754.HK) announced that the audit committee has selected and engaged Deloitte Advisory (Hong Kong) Limited as the independent internal control consultant to conduct an independent internal control review as required under the resumption guidance, expected to be completed by the end of September 2026; the Company's shares have been suspended since 1 April 2026 and will remain suspended.
Tag： HOPSON DEV HOLD00754.HKInternal Controlresumption guidance
18:34
[ EXTREME VISION (06636.HK): Proposes H-share full circulation, filing application for conversion of 562,347 unlisted shares ] NewTimeSpace News: On 26 August 2026, EXTREME VISION (06636.HK) announced that the board has approved the proposed implementation of H-share full circulation and submitted a filing application to the CSRC for the conversion of 562,347 domestic unlisted shares held by one shareholder (approximately 0.50% of total issued shares) into H shares; upon obtaining the relevant filings and approvals, such shares will be converted into H shares and the Company will apply for their listing and trading on the Main Board of the Stock Exchange.
Tag： EXTREME VISION06636.HKH-share full circulation
18:32
[ MING YUAN CLOUD(00909.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 1.12 million, YoY decrease of 91.88% ] NewTimeSpace News: August 26, 2026, MING YUAN CLOUD(00909.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 525.26 million, decreased by 13.3% YoY.
Tag： MING YUAN CLOUD00909.HKProfit declined
18:32
[ CNOOC(00883.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 85.82 billion, YoY increase of 23.42% ] NewTimeSpace News: August 26, 2026, CNOOC(00883.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 242.66 billion, increased by 16.88% YoY.
Tag： CNOOC00883.HKprofit growth
18:32
[ WING ON CO(00289.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of HKD 91.36 million, loss narrowed by 39.21% YoY ] NewTimeSpace News: August 26, 2026, WING ON CO(00289.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at HKD 430.68 million, increased by 3.47% YoY.
Tag： WING ON CO00289.HKloss narrowed
18:32
[ LEGION CONSO(02129.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at SGD 699.05 thousand, turned profitable from a loss YoY ] NewTimeSpace News: August 26, 2026, LEGION CONSO(02129.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at SGD 32.81 million, increased by 10.7% YoY.
Tag： LEGION CONSO02129.HKturned profitable from loss
18:32
[ FWD (01828.HK): 2026 interim results — profit attributable to shareholders of USD 165 million, up 1550% year-on-year ] NewTimeSpace News: On 26 August 2026, FWD (01828.HK) announced its 2026 interim results, with total revenue of USD 1.576 billion, up 6.34% year-on-year; profit attributable to shareholders of USD 165 million, up 1550% year-on-year.
Tag： FWD01828.HKprofit growth
18:29
[ XINYI ENERGY & XINYI SOLAR (03868.HK/00968.HK): Proposed China listing of Xinyi Energy new energy REIT recommended by NDRC to CSRC ] NewTimeSpace News: On 26 August 2026, XINYI ENERGY (03868.HK) and XINYI SOLAR (00968.HK) jointly announced that the proposed China listing of the Xinyi Energy New Energy REIT, an investment fund holding selected solar power plant projects of Xinyi Energy, has been recommended by the NDRC to the CSRC; the REIT is intended to list on a stock exchange in China, constituting a notifiable transaction and spin-off transaction for both companies.
Tag： XINYI ENERGY03868.HKXINYI SOLAR00968.HKREIT
18:23
[ PATEO (02889.HK): Enters global supply system of leading international automaker, wins dual-brand 8295 platform vehicle designations ] NewTimeSpace News: On 26 August 2026, PATEO (02889.HK) announced that it has entered the global supply system of a leading international automotive group for the first time, securing dual-brand designations covering the global models of a premium luxury brand and the export models of a mid-to-high-end brand, involving overseas markets including Europe, the Middle East and South America; the Company will provide high-end intelligent cockpit domain controllers and AI in-vehicle interaction systems based on Qualcomm's fourth-generation Snapdragon 8295 platform.
Tag： PATEO02889.HKBusiness Contract
18:21
[ CANSINOBIO (06185.HK): Latest progress of mRNA technology platform, subsidiary signs co-development agreement for personalized therapeutic tumor vaccines ] NewTimeSpace News: On 26 August 2026, CANSINOBIO (06185.HK) announced that its mRNA platform is advancing the development of therapeutic biological products and delivery systems, with mRNA vaccines for glioblastoma, rhabdomyosarcoma, cervical cancer and In Vivo CAR-related therapies all at an early stage; its subsidiary CanSino Shanghai has entered into a strategic cooperation framework agreement with Depushi (Hangzhou) Biotechnology for the co-development of mRNA personalized therapeutic tumor vaccines.
Tag： CANSINOBIO06185.HKR&D Progress
Previous1..113114 115116117..576     576 pages total
×
Share to WeChat

Open WeChat, use "Scan," and share to my Moments